Treatment effect and safety profile of salvage chemotherapy following immune checkpoint inhibitors in lung cancer

被引：14
|
作者：
Tone, Mari [1 ]
Izumo, Takehiro [1 ]
Awano, Nobuyasu [1 ]
Kuse, Naoyuki [1 ]
Inomata, Minoru [1 ]
Jo, Tatsunori [1 ]
Yoshimura, Hanako [1 ]
Miyamoto, Shingo [2 ]
Kunitoh, Hideo [2 ]
机构：
[1] Japanese Red Cross Med Ctr, Dept Resp Med, Shibuya Ku, Tokyo, Japan
[2] Japanese Red Cross Med Ctr, Dept Med Oncol, Shibuya Ku, Tokyo, Japan
来源：
LUNG CANCER MANAGEMENT | 2019年 / 8卷 / 02期
关键词：
immune checkpoint inhibitor; NSCLC; salvage chemotherapy; RANDOMIZED PHASE-III; RESPONSE RATES; DOCETAXEL; NIVOLUMAB; PEMBROLIZUMAB; VINORELBINE; CARBOPLATIN; TRIAL; CELLS;
D O I：
10.2217/lmt-2019-0001
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
Aim: To assess the relationship of treatment effects between immune checkpoint inhibitor (ICI) and salvage chemotherapy, with the safety profile of salvage chemotherapy. Patients & methods: 18 patients with advanced NSCLC treated using salvage chemotherapy following ICI treatment were retrospectively included. We assessed the overall response rate to and adverse events of salvage chemotherapy. Results: The overall response rate to salvage chemotherapy was 33.3% and that of ICI responders was significantly higher than that of ICI nonresponders (66.7 vs 16.7%, respectively, p = 0.03). The incidence rate of adverse events to salvage chemotherapy was 55.6%. Conclusion: The efficacy of salvage chemotherapy was similar to that preceding ICI. Moreover, the safety of salvage chemotherapy was good.
引用
收藏
页数：7
相关论文
共 50 条
  • [41] Immune checkpoint inhibitors:breakthroughs in cancer treatment
    Xueqing Kong
    Jinyi Zhang
    Shuwei Chen
    Xianyang Wang
    Qing Xi
    Han Shen
    Rongxin Zhang
    Cancer Biology & Medicine, 2024, 21 (06) : 451 - 472
  • [42] Immune checkpoint inhibitors: breakthroughs in cancer treatment
    Kong, Xueqing
    Zhang, Jinyi
    Chen, Shuwei
    Wang, Xianyang
    Xi, Qing
    Shen, Han
    Zhang, Rongxin
    CANCER BIOLOGY & MEDICINE, 2024, 21 (06) : 451 - 472
  • [43] Immune Checkpoint Inhibitors in the Treatment of Gastroesophageal Cancer
    Chenard-Poirier, Maxime
    Smyth, Elizabeth C.
    DRUGS, 2019, 79 (01) : 1 - 10
  • [44] Immune Checkpoint Inhibitors in the Treatment of Gastroesophageal Cancer
    Maxime Chénard-Poirier
    Elizabeth C. Smyth
    Drugs, 2019, 79 : 1 - 10
  • [45] Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer
    Lopez-Beltran, Antonio
    Cimadamore, Alessia
    Blanca, Ana
    Massari, Francesco
    Vau, Nuno
    Scarpelli, Marina
    Cheng, Liang
    Montironi, Rodolfo
    CANCERS, 2021, 13 (01) : 1 - 16
  • [46] Gastrointestinal cancer treatment with immune checkpoint inhibitors
    Kim, Jin Won
    JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2021, 64 (05): : 342 - 348
  • [47] Review of cancer treatment with immune checkpoint inhibitors
    Thallinger, Christiane
    Fuereder, Thorsten
    Preusser, Matthias
    Heller, Gerwin
    Muellauer, Leonhard
    Hoeller, Christoph
    Prosch, Helmut
    Frank, Natalija
    Swierzewski, Rafal
    Berger, Walter
    Jaeger, Ulrich
    Zielinski, Christoph
    WIENER KLINISCHE WOCHENSCHRIFT, 2018, 130 (3-4) : 85 - 91
  • [48] Immune checkpoint inhibitors in cancer treatment and potential effect modification by age
    Eriksson, Hanna
    Smedby, Karin E.
    ACTA ONCOLOGICA, 2020, 59 (03) : 247 - 248
  • [49] Immune Checkpoint Inhibitors in Lung Cancer: Imaging Considerations
    Wang, Gary X.
    Guo, Lan Qian
    Gainor, Justin F.
    Fintelmann, Florian J.
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2017, 209 (03) : 567 - 575
  • [50] Immune checkpoint inhibitors in small cell lung cancer
    Pakkala, Suchita
    Owonikoko, Taofeek K.
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S460 - S467
12345